JP6102234B2 - Medical multi-layer container - Google Patents

Description

  The present invention relates to a medical container having an oxygen barrier performance and an oxygen absorption function.

  Prevents oxygen oxidation of various products that are easily altered or deteriorated by the influence of oxygen, such as food, beverages, pharmaceuticals, and cosmetics, and removes oxygen in the package that contains them for the purpose of long-term storage. The oxygen absorber to be used is used.

  As the oxygen absorbent, an oxygen absorbent containing iron powder as a main reaction agent is generally used from the viewpoint of oxygen absorption capacity, ease of handling, and safety. However, since this iron-based oxygen absorbent is sensitive to a metal detector, it has been difficult to use the metal detector for foreign object inspection. In addition, since the package containing the iron-based oxygen absorbent requires water for the oxidation reaction of the iron powder, it can exhibit the effect of oxygen absorption only if the object to be preserved is a high-water content. could not.

  In addition, the container is made of a multilayer material in which an oxygen absorbing layer made of an oxygen absorbing resin composition in which an iron-based oxygen absorber is blended with a thermoplastic resin, thereby improving the gas barrier property of the container and improving the container itself. Development of packaging containers having an oxygen absorbing function has been carried out (see Patent Document 1). Specifically, in this multilayer material, an oxygen absorption layer made of a thermoplastic resin in which an iron-based oxygen absorbent is dispersed is provided between layers of a gas barrier multilayer film having a conventional structure in which a heat seal layer and a gas barrier layer are laminated. This is an oxygen-absorbing multilayer film, which has a function of absorbing oxygen in the container in addition to the function of preventing oxygen permeation from the outside, and is conventionally known as extrusion lamination, co-extrusion lamination, dry lamination, etc. It is manufactured using the manufacturing method. However, this also has the problem that the object to be preserved is only effective when detected by a metal detector used for detecting foreign substances such as foods. Furthermore, there is a problem that the internal visibility is insufficient due to the problem of opacity.

  In view of the above circumstances, an oxygen absorbent using an organic substance as a reaction main agent is desired. As an oxygen absorbent containing an organic substance as a main reaction agent, an oxygen absorbent containing ascorbic acid as a main agent is known (see Patent Document 2).

  On the other hand, an oxygen-absorbing resin composition comprising a resin and a transition metal catalyst is known. For example, a resin composition comprising a polyamide, particularly a xylylene group-containing polyamide and a transition metal catalyst as an oxidizable organic component is known (see Patent Documents 3 and 4). Further, Patent Documents 3 and 4 also exemplify an oxygen absorbent, a packaging material, and a multilayer laminated film for packaging obtained by molding this resin composition.

  As an oxygen-absorbing resin composition that does not require moisture for oxygen absorption, an oxygen-absorbing resin composition comprising a resin having a carbon-carbon unsaturated bond and a transition metal catalyst is known (see Patent Document 5). .

  Furthermore, as a composition for collecting oxygen, a composition comprising a polymer containing a substituted cyclohexene functional group or a low molecular weight substance to which the cyclohexene ring is bonded and a transition metal is known (see Patent Document 6).

  On the other hand, glass ampules, vials, prefilled syringes, and the like have been conventionally used as medical packaging containers for filling and storing chemical solutions in a sealed state. However, these glass containers are colored when a light-shielding glass container colored with metal is used, in which sodium ions and the like are eluted in the liquid in the container during storage, and a fine substance called flakes is generated. There is a problem that the metal for use is mixed into the contents and is easily broken by an impact such as dropping. Further, since the specific gravity is relatively large, there is a problem that the medical packaging container is heavy. Therefore, development of alternative materials is expected. Specifically, plastics that are lighter than glass, such as polyester, polycarbonate, polypropylene, and cycloolefin polymers, are being considered as glass substitutes.

  For example, a medical container made of a polyester resin material has been proposed (see Patent Document 7).

  On the other hand, in order to provide a gas barrier property to a container made of plastic, a multilayer container having a gas barrier layer as an intermediate layer has been studied. Specifically, a prefilled syringe with improved oxygen barrier properties, which has an innermost layer and an outermost layer made of a polyolefin-based resin, and an intermediate layer made of a resin composition excellent in oxygen barrier properties, has been presented (Patent Literature). 8). In addition, polyamide obtained from metaxylylenediamine and adipic acid (hereinafter sometimes referred to as “nylon MXD6”), ethylene-vinyl alcohol copolymer, polyacrylonitrile, polyvinylidene chloride, aluminum foil, carbon Multi-layer containers in which a gas barrier layer such as a coat or inorganic oxide deposition is laminated on a resin layer are also being studied.

  On the other hand, in recent years, it has been proposed that a small amount of transition metal compound is added to and mixed with nylon MXD6 to give an oxygen absorbing function, and this is used as an oxygen barrier material constituting containers and packaging materials ( (See Patent Document 9).

  In addition to ampoules, vials, and syringes, examples of medical containers include artificial kidney hemodialyzers (dialyzers). For the housing of the dialyzer, polystyrene or polycarbonate is used as a transparent plastic that allows the contents to be clearly seen. However, in order to avoid damage due to dropping or other impact, polycarbonate having good impact resistance is more preferred ( (See Patent Document 10).

Japanese Patent Application Laid-Open No. 09-234832 JP-A-51-136845 JP 2001-252560 A JP 2009-108153 A Japanese Patent Laid-Open No. 05-115776 Special table 2003-521552 gazette JP 08-127641 A JP 2004-229750 A Japanese Patent Laid-Open No. 02-500846 Japanese Patent Laid-Open No. 01-259870

  However, the oxygen absorbent of Patent Document 2 has a problem that oxygen absorption performance is low in the first place, and only a high-moisture material is effective and is relatively expensive.

  Moreover, since the resin composition of patent document 3 expresses an oxygen absorption function by containing a transition metal catalyst and oxidizing a xylylene group-containing polyamide resin, the polymer chain due to oxidative degradation of the resin after oxygen absorption. There is a problem that cutting occurs and the strength of the packaging container itself is reduced. Furthermore, this resin composition has a problem that oxygen absorption performance is still insufficient, and the object to be preserved exhibits only an effect of high moisture. Further, Patent Document 4 describes a method for improving delamination, but the effect is limited. Furthermore, this resin composition has a problem that oxygen absorption performance is still insufficient, and the object to be preserved exhibits only an effect of high moisture.

  Furthermore, the oxygen-absorbing resin composition of Patent Document 5 generates a low molecular weight organic compound that becomes an odor component by breaking the polymer chain accompanying the oxidation of the resin in the same manner as described above, and generates odor after oxygen absorption. There's a problem.

  On the other hand, the composition of Patent Document 6 needs to use a special material containing a cyclohexene functional group, and this material still has a problem that it is relatively easy to generate an odor.

  On the other hand, the above-mentioned conventional medical multi-layer container has insufficient basic performance such as oxygen barrier property, water vapor barrier property, chemical solution adsorption property, and container durability, and is therefore improved from the viewpoint of storage stability of contents such as chemical solution. Is required.

  In particular, when storing a chemical solution using a conventional gas barrier multi-layer container, it is difficult or extremely uneconomical to completely remove oxygen in the packaging container no matter how the gas replacement operation is performed. There is. That is, it is difficult to completely eliminate oxygen dissolved in the liquid of the contents, oxygen contained in bubbles generated and mixed when the contents are mixed, water added thereto, and the like. Although it is possible to remove oxygen as much as possible by performing advanced management in the selection / preparation conditions and manufacturing conditions of raw materials, such handling that ignores economic efficiency is not realistic. In addition, since the oxygen barrier property of the gas barrier multilayer container is not sufficient as described above, it is not possible to completely eliminate the trace amount of oxygen that permeates through the wall of the container and enters from the outside.

  For example, although the medical container made of polyester resin of Patent Document 7 has relatively excellent oxygen barrier property, the oxygen barrier property is insufficient to completely block oxygen, and the polyolefin resin Compared to a container made of, the water vapor barrier property is also inferior. Moreover, this polyester resin does not have oxygen absorption performance. Therefore, when oxygen enters the container from the outside, or oxygen remains in the head space existing above the contents of the container, there is a problem in that the chemical solution in the container cannot be prevented from deteriorating. there were.

  Moreover, although the prefilled syringe of patent document 8 has relatively excellent oxygen barrier property and water vapor barrier property, the oxygen barrier property is insufficient to completely block oxygen. And the oxygen barrier resin composition of an intermediate | middle layer does not have oxygen absorption performance. Therefore, when oxygen enters the container from the outside, or oxygen remains in the head space existing above the contents of the container, there is a problem in that the chemical solution in the container cannot be prevented from deteriorating. there were.

  On the other hand, the resin composition of Patent Document 9 has a problem that, as in Patent Documents 3 and 4 described above, a decrease in strength occurs due to oxidative degradation of the resin after oxidative absorption, and the strength of the packaging container itself decreases. Yes. Furthermore, this resin composition has a problem that oxygen absorption performance is still insufficient, and the object to be preserved exhibits only an effect of high moisture.

  The housing of the dialyzer disclosed in Patent Document 10 has excellent transparency and impact resistance, but polycarbonate is insufficient in oxygen barrier property and water vapor barrier property to be applied to a container for storing and storing a chemical solution. There is a problem in terms of long-term storage of the contents.

  The present invention has been made in view of the above problems, and its purpose is to significantly suppress the formation of low molecular weight compounds after oxygen absorption, and to have excellent oxygen barrier performance, preferably excellent water vapor barrier performance. Another object of the present invention is to provide a novel oxygen-absorbing medical multilayer molded container that maintains its strength even during long-term storage and has an extremely small amount of impurity elution. Another object of the present invention is to provide an oxygen-absorbing medical multilayer molded container having excellent oxygen absorption performance under a wide range of humidity conditions from low humidity to high humidity.

  As a result of earnestly examining the oxygen-absorbing medical multilayer molded container, the present inventors have found that the above problem can be solved by using a polyamide compound having a predetermined tetralin ring and a transition metal catalyst. The present invention has been completed.

（式中、Ｒは、それぞれ独立して、一価の置換基を示し、一価の置換基は、ハロゲン原子、アルキル基、アルケニル基、アルキニル基、アリール基、複素環基、シアノ基、ヒドロキシ基、カルボキシル基、エステル基、アミド基、ニトロ基、アルコキシ基、アリールオキシ基、アシル基、アミノ基、メルカプト基、アルキルチオ基、アリールチオ基、複素環チオ基およびイミド基からなる群より選択される少なくとも１種であり、これらはさらに置換基を有していてもよい。各式中、ｍは、それぞれ独立して、０〜３の整数を示し、各式中、ｎは、それぞれ独立して、０〜７の整数を示し、テトラリン環のベンジル位には少なくとも１つ以上の水素原子が結合している。各式中、Ｘは、それぞれ独立して、芳香族炭化水素基、飽和または不飽和の脂環式炭化水素基、直鎖状または分岐状の飽和または不飽和の脂肪族炭化水素基および複素環基からなる群から選ばれる少なくとも１つの基を含有する２価の基を示す。）
からなる群より選択される少なくとも１つのテトラリン環を有する構成単位を含有する、酸素吸収性医療用多層成形容器。
＜２＞ 前記遷移金属触媒が、マンガン、鉄、コバルト、ニッケルおよび銅からなる群より選択される少なくとも１種以上の遷移金属を含むものである、上記＜１＞に記載の酸素吸収性医療用多層成形容器。
＜３＞ 前記遷移金属触媒が、前記ポリアミド化合物１００質量部に対し、遷移金属量として０．００１〜１０質量部含まれる、上記＜１＞または＜２＞に記載の酸素吸収性医療用多層成形容器。
＜４＞ 前記一般式（１）で表される構成単位が、下記式（３）〜（６）で表される構成単位；

からなる群より選択される少なくとも１つである、上記＜１＞〜＜３＞のいずれかに記載の酸素吸収性医療用多層成形容器。
＜５＞ 前記ポリエステルが、ジカルボン酸単位中の７０モル％以上がテレフタル酸、イソフタル酸、１，３−ナフタレンジカルボン酸、１，４−ナフタレンジカルボン酸、１，５−ナフタレンジカルボン酸、２，６−ナフタレンジカルボン酸、２，７−ナフタレンジカルボン酸からなる群から選ばれる１種以上のジカルボン酸に由来する＜１＞〜＜４＞のいずれか一項に記載の酸素吸収性医療用多層成形容器。
＜６＞ 前記ポリエステルが、ジカルボン酸単位中の７０モル％以上がテレフタル酸に由来する＜１＞〜＜４＞のいずれか一項に記載の酸素吸収性医療用多層成形容器。
＜７＞ 前記ポリエステルが、ジカルボン酸単位中の９０モル％以上がテレフタル酸に由来する＜１＞〜＜４＞いずれか一項に記載の酸素吸収性医療用多層成形容器。
＜８＞ 前記ポリエステルが、ジカルボン酸単位中の７０モル％以上が２，６−ナフタレンジカルボン酸に由来する＜１＞〜＜４＞のいずれか一項に記載の酸素吸収性医療用多層成形容器。
＜９＞ 前記ポリエステルが、ジカルボン酸単位中の９０モル％以上が２，６−ナフタレンジカルボン酸骨格である＜１＞〜＜４＞のいずれか一項に記載の酸素吸収性医療用多層成形容器。 That is, the present invention provides the following <1> to <9>.
<1> At least 3 of the 1st resin layer containing at least polyester, the oxygen absorption layer which consists of an oxygen absorptive resin composition containing a polyamide compound and a transition metal catalyst, and the 2nd resin layer containing at least polyester An oxygen-absorbing medical multilayer molded container having layers in this order,
The polyamide compound is a structural unit represented by the following general formulas (1) to (2);

(In the formula, each R independently represents a monovalent substituent, which is a halogen atom, alkyl group, alkenyl group, alkynyl group, aryl group, heterocyclic group, cyano group, hydroxy group, Selected from the group consisting of a group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, mercapto group, alkylthio group, arylthio group, heterocyclic thio group and imide group And each of them may further have a substituent, wherein each m independently represents an integer of 0 to 3, and in each formula, n is each independently Represents an integer of 0 to 7, and at least one hydrogen atom is bonded to the benzylic position of the tetralin ring, wherein each X is independently an aromatic hydrocarbon group, saturated or unsaturated. Sat It shows the alicyclic hydrocarbon group, a divalent group containing at least one group selected from the group consisting of aliphatic hydrocarbon group and the heterocyclic group of linear or branched, saturated or unsaturated.)
An oxygen-absorbing medical multilayer molded container containing a structural unit having at least one tetralin ring selected from the group consisting of:
<2> The oxygen-absorbing medical multilayer molding according to <1>, wherein the transition metal catalyst includes at least one transition metal selected from the group consisting of manganese, iron, cobalt, nickel, and copper. container.
<3> The oxygen-absorbing medical multilayer molding according to <1> or <2>, wherein the transition metal catalyst is contained in an amount of 0.001 to 10 parts by mass as a transition metal amount with respect to 100 parts by mass of the polyamide compound. container.
<4> The structural unit represented by the general formula (1) is represented by the following formulas (3) to (6);

The oxygen-absorbing medical multilayer molded container according to any one of <1> to <3>, which is at least one selected from the group consisting of:
<5> 70% by mole or more of the polyester in the dicarboxylic acid unit is terephthalic acid, isophthalic acid, 1,3-naphthalenedicarboxylic acid, 1,4-naphthalenedicarboxylic acid, 1,5-naphthalenedicarboxylic acid, 2,6 -Oxygen-absorbing medical multilayer molded container according to any one of <1> to <4>, derived from one or more dicarboxylic acids selected from the group consisting of naphthalenedicarboxylic acid and 2,7-naphthalenedicarboxylic acid .
<6> The oxygen-absorbing medical multilayer molded container according to any one of <1> to <4>, wherein 70% by mole or more of the polyester in the dicarboxylic acid unit is derived from terephthalic acid.
<7> The oxygen-absorbing medical multilayer molded container according to any one of <1> to <4>, wherein 90% by mole or more of the polyester in the dicarboxylic acid unit is derived from terephthalic acid.
<8> The oxygen-absorbing medical multilayer molded container according to any one of <1> to <4>, wherein 70% by mole or more of the polyester is derived from 2,6-naphthalenedicarboxylic acid. .
<9> The oxygen-absorbing medical multilayer molded container according to any one of <1> to <4>, wherein 90% by mole or more of the polyester in the dicarboxylic acid unit is a 2,6-naphthalenedicarboxylic acid skeleton. .

  According to the present invention, a vial, a prefilled syringe, etc. having excellent oxygen absorption performance under a wide range of humidity conditions from low humidity to high humidity, good oxygen barrier properties, and excellent water vapor barrier in a preferred embodiment, etc. The oxygen-absorbing medical multilayer molded container can be realized. The oxygen-absorbing medical multilayer molded container can absorb oxygen regardless of the presence or absence of moisture in the stored object. In addition, since the strength of the polyamide compound having a tetralin ring due to oxidation is very small after oxygen absorption and the strength of the oxygen absorbing layer is maintained even after long-term use, the oxygen-absorbing medical multilayer is less likely to cause delamination. A molded container can also be realized. Furthermore, since the generation of low molecular weight organic compounds after oxygen absorption is remarkably suppressed, it is possible to realize an oxygen-absorbing medical multilayer molded container in which the content of the low molecular weight organic compounds is extremely small. Therefore, the oxygen-absorbing medical multilayer molded container of the present invention is particularly useful for storing pharmaceuticals, biopharmaceuticals, medical products and the like that are required to be stored under a low oxygen concentration.

  Embodiments of the present invention will be described below. In addition, the following embodiment is an illustration for demonstrating this invention, and this invention is not limited only to the embodiment.

  The oxygen-absorbing medical multilayer molded container of the present embodiment includes at least a first resin layer (layer B) containing polyester, an oxygen-absorbing layer (layer A) made of an oxygen-absorbing resin composition, and at least polyester. It has at least 3 layers in this order with the 2nd resin layer (layer B) to contain.

  The oxygen-absorbing medical multilayer molded container of the present embodiment absorbs oxygen in the container, and if there is little oxygen that permeates or penetrates the container wall surface from outside the container, the oxygen-absorbing medical multilayer molded container also has this permeated or infiltrated oxygen. It is possible to prevent alteration or the like due to oxygen of the content article (preservation object) to be absorbed and stored.

  As long as these layers are arranged in the order of B / A / B, the layer structure in the oxygen-absorbing medical multilayer molded container of this embodiment is the number of oxygen-absorbing layers (layer A) and resin layers (layer B). The type is not particularly limited. For example, a five-layer configuration of B1 / B2 / A / B2 / B1 including one layer A, two layers B1, and two layers B2 may be used. Moreover, the oxygen-absorbing medical multilayer molded container of the present embodiment may include an arbitrary layer such as an adhesive layer (layer AD) as necessary. For example, B1 / AD / B2 / A / B2 / AD / A seven-layer configuration of B1 may be used.

[Oxygen absorbing layer (layer A)]
In the oxygen-absorbing medical multilayer molded container of the present embodiment, the oxygen-absorbing layer (layer A) is at least one selected from the group consisting of structural units represented by the above general formulas (1) to (2). It consists of an oxygen-absorbing resin composition containing a polyamide compound containing a structural unit having a tetralin ring (hereinafter also simply referred to as “tetralin ring-containing polyamide compound”) and a transition metal catalyst.

  The content ratio of the tetralin ring-containing polyamide compound in the layer A is not particularly limited, but is preferably 50% by mass or more, more preferably 70% by mass or more, and further preferably 90% by mass or more with respect to the total amount of the layer A. It is. When the content ratio of the tetralin ring-containing polyamide compound is equal to or more than the preferable value, the oxygen absorption performance tends to be further improved as compared with the case where the content is not so.

<Tetralin ring-containing polyamide compound>
The tetralin ring-containing polyamide compound used in the oxygen-absorbing resin composition of the present embodiment contains at least one of the structural units represented by the general formulas (1) to (2). The structural unit represented by the general formula (1) is preferably at least one selected from the group consisting of structural units represented by the above formulas (3) to (6). Here, “containing a structural unit” means that the compound has one or more of the structural unit. Such a structural unit is preferably contained as a repeating unit in the tetralin ring-containing polyamide compound. Thus, when the tetralin ring-containing polyamide compound is a polymer, any one of the homopolymer of the structural unit, a random copolymer of the structural unit and other structural units, and a block copolymer of the structural unit and other structural units. It does not matter.

  In the structural units represented by the general formulas (1) to (2), examples of the monovalent substituent represented by R include a halogen atom (for example, a chlorine atom, a bromine atom, and an iodine atom), an alkyl group (preferably A linear, branched or cyclic alkyl group having 1 to 15 carbon atoms, more preferably 1 to 6 carbon atoms, such as a methyl group, ethyl group, n-propyl group, isopropyl group, t-butyl group, n -Octyl group, 2-ethylhexyl group, cyclopropyl group, cyclopentyl group), alkenyl group (preferably a linear, branched or cyclic alkenyl group having 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, For example, vinyl group, allyl group), alkynyl group (preferably alkynyl group having 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, such as ethynyl group, propargyl group), aryl A group (preferably an aryl group having 6 to 16 carbon atoms, more preferably an aryl group having 6 to 10 carbon atoms, such as a phenyl group or a naphthyl group), a heterocyclic group (preferably having a carbon number of 1 to 12, more preferably carbon A monovalent group obtained by removing one hydrogen atom from a 5-membered or 6-membered aromatic or non-aromatic heterocyclic compound having a number of 2 to 6, such as a 1-pyrazolyl group, 1- Imidazolyl group, 2-furyl group), cyano group, hydroxy group, carboxyl group, ester group, amide group, nitro group, alkoxy group (preferably having 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms). A linear, branched or cyclic alkoxy group such as a methoxy group or an ethoxy group, an aryloxy group (preferably an aryloxy group having 6 to 12 carbon atoms, more preferably 6 to 8 carbon atoms, eg A phenoxy group), an acyl group (including a formyl group, preferably an alkylcarbonyl group having 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, preferably 7 to 12 carbon atoms, more preferably carbon atoms. An arylcarbonyl group having 7 to 9 carbon atoms, for example, an acetyl group, a pivaloyl group, a benzoyl group), an amino group (preferably having 1 to 10 carbon atoms, more preferably an alkylamino group having 1 to 6 carbon atoms, preferably An anilino group having 6 to 12 carbon atoms, more preferably 6 to 8 carbon atoms, preferably a heterocyclic amino group having 1 to 12 carbon atoms, more preferably 2 to 6 carbon atoms, such as an amino group, methyl Amino group, anilino group), mercapto group, alkylthio group (preferably an alkylthio group having 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, such as methylthio group, ethyl Luthio group), an arylthio group (preferably an arylthio group having 6 to 12 carbon atoms, more preferably an arylthio group having 6 to 8 carbon atoms, such as a phenylthio group), a heterocyclic thio group (preferably having 2 to 10 carbon atoms, and more). Preferably a heterocyclic thio group having 1 to 6 carbon atoms, such as a 2-benzothiazolylthio group, an imide group (preferably an imide group having 2 to 10 carbon atoms, more preferably 4 to 8 carbon atoms, Examples thereof include N-succinimide group and N-phthalimide group), but are not particularly limited thereto.

  In addition, when said monovalent substituent R has a hydrogen atom, the hydrogen atom is a substituent T (Here, the substituent T is synonymous with what was demonstrated by said monovalent substituent R.). ) May be further substituted. Specific examples thereof include an alkyl group substituted with a hydroxy group (eg, hydroxyethyl group), an alkyl group substituted with an alkoxy group (eg, methoxyethyl group), and an alkyl group substituted with an aryl group (eg, benzyl). Group), an alkyl group substituted with a primary or secondary amino group (eg, aminoethyl group), an aryl group substituted with an alkyl group (eg, p-tolyl group), an aryl substituted with an alkyl group Examples thereof include, but are not particularly limited to, an oxy group (for example, 2-methylphenoxy group) and the like. When the monovalent substituent R has a monovalent substituent T, the carbon number described above does not include the carbon number of the substituent T. For example, a benzyl group is regarded as a C 1 alkyl group substituted with a phenyl group, and is not regarded as a C 7 alkyl group substituted with a phenyl group. When the monovalent substituent R has a substituent T, there may be a plurality of the substituents T.

In the structural units represented by the general formulas (1) to (2), X is an aromatic hydrocarbon group, a saturated or unsaturated alicyclic hydrocarbon group, a linear or branched saturated or unsaturated group. And a divalent group containing at least one group selected from the group consisting of an aliphatic hydrocarbon group and a heterocyclic group. Aromatic hydrocarbon group, saturated or unsaturated alicyclic hydrocarbon group, linear or branched saturated or unsaturated aliphatic hydrocarbon group and heterocyclic group may be substituted or unsubstituted . X may contain a hetero atom, or may contain an ether group, sulfide group, carbonyl group, hydroxy group, amino group, sulfoxide group, sulfone group or the like.
Here, as the aromatic hydrocarbon group, for example, o-phenylene group, m-phenylene group, p-phenylene group, methylphenylene group, o-xylylene group, m-xylylene group, p-xylylene group, naphthylene group, Anthracenylene group, phenanthrylene group, biphenylene group, fluoronylene group and the like can be mentioned, but not limited thereto. Examples of the alicyclic hydrocarbon group include a cycloalkylene group such as a cyclopentylene group, a cyclohexylene group, a methylcyclohexylene group, a cycloheptylene group, and a cyclooctylene group, and a cycloalkenylene group such as a cyclohexenylene group. Although it is mentioned, it is not specifically limited to these. Examples of the aliphatic hydrocarbon group include methylene group, ethylene group, trimethylene group, propylene group, isopropylidene group, tetramethylene group, isobutylidene group, sec-butylidene group, pentamethylene group, hexamethylene group, heptamethylene group, Linear or branched alkylene groups such as octamethylene group, nonamethylene group, decamethylene group, vinylene group, propenylene group, 1-butenylene group, 2-butenylene group, 1,3-butadienylene group, 1-pentenylene group Alkenylene groups such as 2-pentenylene group, 1-hexenylene group, 2-hexenylene group, 3-hexenylene group and the like, but are not particularly limited thereto. These may further have a substituent, and specific examples thereof include, for example, halogen, alkoxy group, hydroxy group, carboxyl group, carboalkoxy group, amino group, acyl group, thio group (for example, alkylthio group, Phenylthio group, tolylthio group, pyridylthio group, etc.), amino group (for example, unsubstituted amino group, methylamino group, dimethylamino group, phenylamino group, etc.), cyano group, nitro group and the like, but not limited thereto .

  The tetralin ring-containing polyamide compound containing the structural unit represented by the general formula (1) is, for example, polycondensation of a dicarboxylic acid having a tetralin ring or a derivative (I) thereof with a diamine or a derivative (II) thereof. Can be obtained.

（式中、Ｒは、それぞれ独立して、一価の置換基を示し、一価の置換基は、ハロゲン原子、アルキル基、アルケニル基、アルキニル基、アリール基、複素環基、シアノ基、ヒドロキシ基、カルボキシル基、エステル基、アミド基、ニトロ基、アルコキシ基、アリールオキシ基、アシル基、アミノ基、メルカプト基、アルキルチオ基、アリールチオ基、複素環チオ基およびイミド基からなる群より選択される少なくとも１種であり、これらはさらに置換基を有していてもよい。ｍは０〜３の整数を示し、ｎは０〜７の整数を示し、テトラリン環のベンジル位には少なくとも１つ以上の水素原子が結合している。） Examples of the dicarboxylic acid having a tetralin ring or its derivative (I) include compounds represented by the following general formula (7). The dicarboxylic acid having a tetralin ring or its derivative (I) can be used alone or in combination of two or more.

(In the formula, each R independently represents a monovalent substituent, which is a halogen atom, alkyl group, alkenyl group, alkynyl group, aryl group, heterocyclic group, cyano group, hydroxy group, Selected from the group consisting of a group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, mercapto group, alkylthio group, arylthio group, heterocyclic thio group and imide group At least one kind, which may further have a substituent, m represents an integer of 0 to 3, n represents an integer of 0 to 7, and at least one or more at the benzylic position of the tetralin ring Of hydrogen atoms are bonded.)

（式中、Ｒは、それぞれ独立して、一価の置換基を示し、一価の置換基は、ハロゲン原子、アルキル基、アルケニル基、アルキニル基、アリール基、複素環基、シアノ基、ヒドロキシ基、カルボキシル基、エステル基、アミド基、ニトロ基、アルコキシ基、アリールオキシ基、アシル基、アミノ基、メルカプト基、アルキルチオ基、アリールチオ基、複素環チオ基およびイミド基からなる群より選択される少なくとも１種であり、これらはさらに置換基を有していてもよい。ｍは、それぞれ独立して０〜３の整数を示す。） The compound represented by the general formula (7) can be obtained, for example, by reacting a dicarboxylic acid having a naphthalene ring represented by the following general formula (8) or a derivative thereof with hydrogen.

(In the formula, each R independently represents a monovalent substituent, which is a halogen atom, alkyl group, alkenyl group, alkynyl group, aryl group, heterocyclic group, cyano group, hydroxy group, Selected from the group consisting of a group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, mercapto group, alkylthio group, arylthio group, heterocyclic thio group and imide group These are at least one kind, and these may further have a substituent, each m independently represents an integer of 0 to 3.)

  Examples of the diamine or its derivative (II) include ethylene diamine, trimethylene diamine, tetramethylene diamine, pentamethylene diamine, hexamethylene diamine, heptamethylene diamine, octamethylene diamine, nonamethylene diamine, decamethylene diamine, and undecamethylene diamine. , Straight-chain saturated aliphatic diamines such as dodecamethylenediamine and tridecamethylenediamine, 2-methylpentamethylenediamine, 2,2,4-trimethylhexamethylenediamine, 2-methyloctamethylenediamine, 2,4-dimethyloctamethylene Branched saturated aliphatic amines such as diamine, 1,3-cyclohexanediamine, 1,4-cyclohexanediamine, 1,3-bis (aminomethyl) cyclohexane, 1,4-bis (aminomethyl) Alicyclic amines such as cyclohexane, m-xylylenediamine, p-xylylenediamine amine, meta-phenylenediamine, aromatic amines paraphenylenediamine, etc. or their derivatives, and the like. Diamine or its derivative (II) can be used individually by 1 type or in combination of 2 or more types.

  In addition to these diamines, polyvalent amines may be used as necessary. Specific examples of the polyvalent amine include aliphatic polyamines such as diethylenetriamine and triethylenetetramine, aromatic ring-containing polyamines such as 1,3,5-tri (aminomethyl) benzene, 1,3,5-triamine, and the like. And alicyclic polyvalent amines such as (aminomethyl) cyclohexane.

  The tetralin ring-containing polyamide compound containing the structural unit represented by the general formula (2) is, for example, polycondensation of a diamine having a tetralin ring or a derivative (III) thereof and a dicarboxylic acid or a derivative (IV) thereof. Can be obtained.

（式中、Ｒは、それぞれ独立して、一価の置換基を示し、一価の置換基は、ハロゲン原子、アルキル基、アルケニル基、アルキニル基、アリール基、複素環基、シアノ基、ヒドロキシ基、カルボキシル基、エステル基、アミド基、ニトロ基、アルコキシ基、アリールオキシ基、アシル基、アミノ基、メルカプト基、アルキルチオ基、アリールチオ基、複素環チオ基およびイミド基からなる群より選択される少なくとも１種であり、これらはさらに置換基を有していてもよい。ｍは０〜３の整数を示し、ｎは０〜７の整数を示し、テトラリン環のベンジル位には少なくとも１つ以上の水素原子が結合している。） Examples of the diamine having a tetralin ring or a derivative (III) thereof include compounds represented by the following general formula (9). A diamine having a tetralin ring or a derivative (III) thereof can be used alone or in combination of two or more.

(In the formula, each R independently represents a monovalent substituent, which is a halogen atom, alkyl group, alkenyl group, alkynyl group, aryl group, heterocyclic group, cyano group, hydroxy group, Selected from the group consisting of a group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, mercapto group, alkylthio group, arylthio group, heterocyclic thio group and imide group At least one kind, which may further have a substituent, m represents an integer of 0 to 3, n represents an integer of 0 to 7, and at least one or more at the benzylic position of the tetralin ring Of hydrogen atoms are bonded.)

（式中、Ｒは、それぞれ独立して、一価の置換基を示し、一価の置換基は、ハロゲン原子、アルキル基、アルケニル基、アルキニル基、アリール基、複素環基、シアノ基、ヒドロキシ基、カルボキシル基、エステル基、アミド基、ニトロ基、アルコキシ基、アリールオキシ基、アシル基、アミノ基、メルカプト基、アルキルチオ基、アリールチオ基、複素環チオ基およびイミド基からなる群より選択される少なくとも１種であり、これらはさらに置換基を有していてもよい。ｍは、それぞれ独立して０〜３の整数を示す。） The compound represented by the general formula (9) can be obtained, for example, by reacting a diamine having a naphthalene ring represented by the following general formula (10) or a derivative thereof with hydrogen.

(In the formula, each R independently represents a monovalent substituent, which is a halogen atom, alkyl group, alkenyl group, alkynyl group, aryl group, heterocyclic group, cyano group, hydroxy group, Selected from the group consisting of a group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, mercapto group, alkylthio group, arylthio group, heterocyclic thio group and imide group These are at least one kind, and these may further have a substituent, each m independently represents an integer of 0 to 3.)

  Examples of the dicarboxylic acid or its derivative (IV) include oxalic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, undecanedioic acid, dodecanedioic acid, 3,3-dimethylpentanedioic acid, and phthalic acid. Benzenedicarboxylic acid such as isophthalic acid and terephthalic acid, naphthalenedicarboxylic acid such as 2,6-naphthalenedicarboxylic acid, anthracene dicarboxylic acid, phenylmalonic acid, phenylenediacetic acid, phenylenedibutyric acid, 4,4-diphenyletherdicarboxylic acid, p -Phenylenedicarboxylic acid or derivatives thereof. Dicarboxylic acid or its derivative (IV) can be used individually by 1 type or in combination of 2 or more types.

  In addition to these dicarboxylic acids, a polyvalent carboxylic acid may be used as necessary. Specific examples of the polyvalent carboxylic acid include ethanetricarboxylic acid, propanetricarboxylic acid, butanetetracarboxylic acid, pyromellitic acid, trimellitic acid, trimesic acid, 3,4,3 ′, 4′-biphenyltetracarboxylic acid, and These ester-forming derivatives are listed.

（式中、Ｒは、それぞれ独立して、一価の置換基を示し、一価の置換基は、ハロゲン原子、アルキル基、アルケニル基、アルキニル基、アリール基、複素環基、シアノ基、ヒドロキシ基、カルボキシル基、エステル基、アミド基、ニトロ基、アルコキシ基、アリールオキシ基、アシル基、アミノ基、メルカプト基、アルキルチオ基、アリールチオ基、複素環チオ基およびイミド基からなる群より選択される少なくとも１種であり、これらはさらに置換基を有していてもよい。ｍは、それぞれ独立して０〜３の整数を示す。Ｘは芳香族炭化水素基、飽和または不飽和の脂環式炭化水素基、直鎖状または分岐状の飽和または不飽和の脂肪族炭化水素基および複素環基からなる群から選ばれる少なくとも１つの基を含有する２価の基を示す。）

（式中、Ｒは、それぞれ独立して、一価の置換基を示し、一価の置換基は、ハロゲン原子、アルキル基、アルケニル基、アルキニル基、アリール基、複素環基、シアノ基、ヒドロキシ基、カルボキシル基、エステル基、アミド基、ニトロ基、アルコキシ基、アリールオキシ基、アシル基、アミノ基、メルカプト基、アルキルチオ基、アリールチオ基、複素環チオ基およびイミド基からなる群より選択される少なくとも１種であり、これらはさらに置換基を有していてもよい。ｍは、それぞれ独立して０〜３の整数を示す。Ｘは芳香族炭化水素基、飽和または不飽和の脂環式炭化水素基、直鎖状または分岐状の飽和または不飽和の脂肪族炭化水素基および複素環基からなる群から選ばれる少なくとも１つの基を含有する２価の基を示す。） Moreover, the tetralin ring containing polyamide compound containing the structural unit represented by the said general formula (1) or (2) is a polyamide containing the structural unit represented by the following general formula (11) or (12), for example It can be obtained by reacting the compound with hydrogen.

(In the formula, each R independently represents a monovalent substituent, which is a halogen atom, alkyl group, alkenyl group, alkynyl group, aryl group, heterocyclic group, cyano group, hydroxy group, Selected from the group consisting of a group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, mercapto group, alkylthio group, arylthio group, heterocyclic thio group and imide group At least one kind, which may further have a substituent, each m independently represents an integer of 0 to 3. X is an aromatic hydrocarbon group, a saturated or unsaturated alicyclic group. And a divalent group containing at least one group selected from the group consisting of a hydrocarbon group, a linear or branched saturated or unsaturated aliphatic hydrocarbon group and a heterocyclic group.)

(In the formula, each R independently represents a monovalent substituent, which is a halogen atom, alkyl group, alkenyl group, alkynyl group, aryl group, heterocyclic group, cyano group, hydroxy group, Selected from the group consisting of a group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, mercapto group, alkylthio group, arylthio group, heterocyclic thio group and imide group At least one kind, which may further have a substituent, each m independently represents an integer of 0 to 3. X is an aromatic hydrocarbon group, a saturated or unsaturated alicyclic group. And a divalent group containing at least one group selected from the group consisting of a hydrocarbon group, a linear or branched saturated or unsaturated aliphatic hydrocarbon group and a heterocyclic group.)

  Specific examples of the monovalent substituent represented by R and the divalent group represented by X in the structural units represented by the general formulas (7) to (12) include the general formulas (1) to (2). It is the same as that described in the structural unit represented by Therefore, the duplicate description here is omitted.

（式中、ｌは、２〜１８の整数を表す。） The tetralin ring-containing polyamide compound used in the oxygen-absorbing resin composition of the present embodiment is a structural unit having another tetralin ring other than the structural units represented by the general formulas (1) to (2), and / or Or the structural unit which does not have a tetralin ring may be included as a copolymerization component. Specifically, the compounds shown in the aforementioned diamine or its derivative (II) or dicarboxylic acid or its derivative (IV) can be used as a copolymerization component. Moreover, you may further contain the omega-aminocarboxylic acid unit represented by the following general formula (13).

(In the formula, l represents an integer of 2 to 18.)

  Examples of the compound that can constitute the ω-aminocarboxylic acid unit represented by the general formula (13) include ω-aminocarboxylic acid having 3 to 19 carbon atoms and lactam having 3 to 19 carbon atoms. Examples of the ω-aminocarboxylic acid having 3 to 19 carbon atoms include 6-aminohexanoic acid and 12-aminododecanoic acid. Examples of the lactam having 3 to 19 carbon atoms include ε-caprolactam and laurolactam. However, it is not limited to these. These can be used alone or in combination of two or more.

  Among the tetralin ring-containing polyamide compounds containing the structural unit represented by the general formula (1), a tetralin ring containing the structural units represented by the above formulas (3) to (6) is more preferable. And a containing polyamide compound.

The molecular weight of the tetralin ring-containing polyamide compound can be appropriately set in consideration of desired performance and handling properties, and is not particularly limited. In general, the weight average molecular weight (Mw) is preferably 1.0 × 10 ^{3 to} 8.0 × 10 ⁶ , more preferably 5.0 × 10 ^{3 to} 5.0 × 10 ⁶ . Similarly, the number average molecular weight (Mn) is preferably 1.0 × 10 ^{3 to} 1.0 × 10 ⁶ , more preferably 5.0 × 10 ^{3 to} 5.0 × 10 ⁴ . In addition, all the molecular weights here mean the value of polystyrene conversion. In addition, said tetralin ring containing polyamide compound can be used individually by 1 type or in combination of 2 or more types.

  Moreover, although the glass transition temperature (Tg) of said tetralin ring containing polyamide compound is not specifically limited, It is preferable that it is 0-150 degreeC, More preferably, it is 10-130 degreeC. The glass transition temperature here means a value measured by differential scanning calorimetry.

  The method for producing the tetralin ring-containing polyamide compound is not particularly limited, and any conventionally known method for producing polyamide can be applied. Examples of the method for producing polyamide include a pressurized salt method, a normal pressure dropping method, and a pressure dropping method. Among these, the pressurized salt method is preferable.

  The pressurized salt method is a method of performing polycondensation under pressure using a salt of dicarboxylic acid and diamine as raw materials. Specifically, after preparing an aqueous solution containing a salt of a dicarboxylic acid and a diamine in a set molar ratio composed of a dicarboxylic acid and a diamine, the aqueous solution is concentrated and then heated under pressure to remove condensed water. This is a method of polycondensation.

  The normal pressure dropping method is a method in which after dicarboxylic acid is heated and melted, a diamine component is continuously dropped under normal pressure to perform polycondensation while removing condensed water. At this time, the polycondensation reaction is performed while raising the temperature so that the reaction temperature does not fall below the melting point of the polyamide to be produced. When the set molar ratio is reached, the dropwise addition of the diamine is terminated, the temperature is raised to a temperature about 10 ° C. higher than the melting point of the polyamide, and the polycondensation is continued for a predetermined time.

  In the pressure dropping method, after the dicarboxylic acid component is heated and melted, the pressure is preferably increased to about 0.3 to 0.4 MPaG, the diamine component is continuously dropped, and the condensed water is removed. This is a method of polycondensation. At this time, the polycondensation reaction is performed while raising the temperature so that the reaction temperature does not fall below the melting point of the polyamide to be produced. When the set molar ratio is reached, the dropping of the diamine component is terminated, and while gradually returning to normal pressure, the temperature is raised to a temperature about 10 ° C. higher than the melting point of the polyamide and maintained for a predetermined time to continue polycondensation.

  The polyamide produced by the polycondensation method can be used as it is, but may be subjected to a step for further increasing the degree of polymerization. Further examples of the step of increasing the degree of polymerization include reactive extrusion in an extruder and solid phase polymerization. As a heating device used in solid phase polymerization, a continuous heating drying device, a tumble dryer, a conical dryer, a rotary drum heating device called a rotary dryer, etc., and a rotary blade inside a nauta mixer are provided. A conical heating device can be preferably used, but a known method and device can be used without being limited thereto. Especially in the case of solid-phase polymerization of polyamide, the rotary drum type heating device in the above-mentioned device can seal the inside of the system, and it is easy to proceed with polycondensation in a state where oxygen that causes coloring is removed. Preferably used.

  In the production of the tetralin ring-containing polyamide compound, any conventionally known ones such as various stabilizers such as a heat stabilizer and a light stabilizer, and a polymerization regulator can be used. These types and amounts used may be appropriately selected according to the reaction rate, the molecular weight of the tetralin ring-containing polyamide compound, the glass transition temperature, the viscosity, the color tone, the safety, the thermal stability, the weather resistance, and the elution property of itself. There is no particular limitation.

The preferred relative viscosity of the tetralin ring-containing polyamide compound is preferably 1.8 to 4.2, more preferably 1.9 to 4.0, and still more preferably, from the viewpoints of strength and appearance of the molded product and molding processability. Is 2.0 to 3.8.
The relative viscosity here refers to 96% measured in the same manner as the dropping time (t) measured at 25 ° C. with a Cannon Fenceke viscometer by dissolving 1 g of a tetralin ring-containing polyamide compound in 100 mL of 96% sulfuric acid. It is the ratio of the drop time (t ₀ ) of sulfuric acid itself, and is represented by the following formula.
Relative viscosity = t / t ₀

  All of the above-mentioned tetralin ring-containing polyamide compounds have hydrogen at the benzylic position of the tetralin ring, and when used in combination with the above-described transition metal catalyst, hydrogen at the benzylic position is extracted, thereby providing an excellent oxygen absorption capacity. Is expressed.

  Moreover, the oxygen-absorbing resin composition of the present embodiment is one in which the generation of low molecular weight compounds after oxygen absorption is remarkably suppressed. Although the reason is not clear, for example, the following oxidation reaction mechanism is assumed. That is, in the above-described tetralin ring-containing polyamide compound, hydrogen at the benzylic position of the tetralin ring is first extracted to generate a radical, and then the carbon at the benzylic position is oxidized by the reaction between the radical and oxygen to produce a hydroxy group or It is thought that a ketone group is formed. Therefore, in the oxygen-absorbing resin composition of the present embodiment, the molecular chain of the oxygen-absorbing main agent is not broken by the oxidation reaction as in the prior art, the structure of the tetralin ring-containing polyamide compound is maintained, and impurities are eluted. This is presumably because the low molecular weight organic compound is difficult to be formed after oxygen absorption.

<Transition metal catalyst>
The transition metal catalyst used in the oxygen-absorbing resin composition of the present embodiment is appropriately selected from known ones as long as it can function as a catalyst for the oxidation reaction of the tetralin ring-containing polyamide compound. There is no particular limitation.

  Specific examples of such transition metal catalysts include organic acid salts, halides, phosphates, phosphites, hypophosphites, nitrates, sulfates, oxides and hydroxides of transition metals. Here, examples of the transition metal contained in the transition metal catalyst include, but are not limited to, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, ruthenium, and rhodium. Among these, manganese, iron, cobalt, nickel, and copper are preferable. Examples of organic acids include acetic acid, propionic acid, octanoic acid, lauric acid, stearic acid, acetylacetone, dimethyldithiocarbamic acid, palmitic acid, 2-ethylhexanoic acid, neodecanoic acid, linoleic acid, toluic acid, oleic acid, Examples include capric acid and naphthenic acid, but are not limited thereto. The transition metal catalyst is preferably a combination of the above transition metal and an organic acid, the transition metal is manganese, iron, cobalt, nickel or copper, and the organic acid is acetic acid, stearic acid, 2-ethylhexanoic acid, olein. A combination that is an acid or naphthenic acid is more preferred. In addition, a transition metal catalyst can be used individually by 1 type or in combination of 2 or more types.

  The content ratio of the tetralin ring-containing polyamide compound and the transition metal catalyst in the oxygen-absorbing resin composition of the present embodiment can be appropriately set according to the type and desired performance of the tetralin ring-containing polyamide compound and the transition metal catalyst to be used. Yes, it is not particularly limited. From the viewpoint of the oxygen absorption amount of the oxygen-absorbing resin composition, the content of the transition metal catalyst is preferably 0.001 to 10 parts by mass as a transition metal amount with respect to 100 parts by mass of the tetralin ring-containing polyamide compound. More preferably, it is 0.002-2 mass part, More preferably, it is 0.005-1 mass part.

<Other thermoplastic resins>
Moreover, the oxygen-absorbing resin composition of this embodiment may further contain other thermoplastic resins other than the said tetralin ring containing polyamide compound as needed. By using another thermoplastic resin in combination, moldability and handleability can be improved.
As other thermoplastic resins, known ones can be used as appropriate. Low density polyethylene, medium density polyethylene, high density polyethylene, linear low density polyethylene, linear ultra low density polyethylene, polypropylene, poly-1-butene, poly-4-methyl-1-pentene, or ethylene, propylene, 1- Polyolefins such as random or block copolymers of α-olefins such as butene and 4-methyl-1-pentene; acid-modified polyolefins such as maleic anhydride grafted polyethylene and maleic anhydride grafted polypropylene; ethylene-vinyl acetate copolymers , Ethylene-vinyl chloride copolymers, ethylene- (meth) acrylic acid copolymers and their ionic cross-linked products (ionomers), ethylene-vinyl compound copolymers such as ethylene-methyl methacrylate copolymers; polystyrene, acrylonitrile- Styrene copolymer, α -Styrenic resin such as methylstyrene-styrene copolymer; polyvinyl compounds such as polymethyl acrylate and polymethyl methacrylate, nylon 6, nylon 66, nylon 610, nylon 12, polymetaxylylene adipamide (MXD6), etc. Polyamide: Polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polytrimethylene terephthalate (PTT), polyethylene naphthalate (PEN), glycol-modified polyethylene terephthalate (PETG), polyethylene succinate (PES), polybutylene succinate (PBS), polyester such as polylactic acid, polyglycolic acid, polycaprolactone, polyhydroxyalkanoate; polycarbonate; polyether such as polyethylene oxide, etc. Although such mixtures thereof, without limitation. These thermoplastic resins can be used individually by 1 type or in combination of 2 or more types.

  The tetralin ring-containing polyamide compound, the transition metal catalyst, and the thermoplastic resin contained as necessary can be mixed by a known method. Moreover, the oxygen-absorbing resin composition which has higher dispersibility can also be obtained by kneading | mixing these using an extruder.

<Various additives>
Here, the oxygen-absorbing resin composition of the present embodiment may contain various additives known in the art as long as the effects of the present embodiment are not excessively impaired. Examples of such optional components include additives such as desiccants, pigments, dyes, antioxidants, slip agents, antistatic agents, stabilizers, fillers such as calcium carbonate, clay, mica, silica, and deodorants. However, it is not particularly limited to these.

  Furthermore, the oxygen-absorbing resin composition of the present embodiment may further contain a radical generator and a photoinitiator as necessary in order to promote the oxygen absorption reaction. Specific examples of the radical generator include various N-hydroxyimide compounds. Specifically, N-hydroxysuccinimide, N-hydroxymaleimide, N, N′-dihydroxycyclohexanetetracarboxylic diimide, N-hydroxyphthalimide, N-hydroxytetrachlorophthalimide, N-hydroxytetrabromophthalimide, N-hydroxy Hexahydrophthalimide, 3-sulfonyl-N-hydroxyphthalimide, 3-methoxycarbonyl-N-hydroxyphthalimide, 3-methyl-N-hydroxyphthalimide, 3-hydroxy-N-hydroxyphthalimide, 4-nitro-N-hydroxyphthalimide, 4-chloro-N-hydroxyphthalimide, 4-methoxy-N-hydroxyphthalimide, 4-dimethylamino-N-hydroxyphthalimide, 4-carboxy-N-hydroxyhexahydride Examples include phthalimide, 4-methyl-N-hydroxyhexahydrophthalimide, N-hydroxyhetic acid imide, N-hydroxyhymic acid imide, N-hydroxytrimellitic acid imide, N, N-dihydroxypyromellitic acid diimide and the like. However, it is not particularly limited to these. Specific examples of the photoinitiator include, but are not limited to, benzophenone and its derivatives, thiazine dyes, metal porphyrin derivatives, anthraquinone derivatives, and the like. These radical generators and photoinitiators can be used singly or in combination of two or more.

  In the oxygen-absorbing medical multilayer molded container of the present embodiment, the thickness of the oxygen-absorbing layer (layer A) can be appropriately set according to the application and desired performance, and is not particularly limited, but has high oxygen-absorbing performance, From the viewpoint of ensuring various physical properties required for the medical multilayer molded container, the thickness is preferably 1 to 1000 μm, more preferably 50 to 900 μm, and still more preferably 100 to 800 μm.

[Resin layer containing polyester (layer B)]
In the oxygen-absorbing medical multilayer molded container of the present embodiment, the resin layer (layer B) is a layer containing polyester. The content of the polyester in the layer B can be appropriately set and is not particularly limited, but is preferably 70 to 100% by mass, more preferably 80 to 100% by mass, further based on the total amount of the layer B. Preferably it is 90-100 mass%.

  The oxygen-absorbing medical multilayer molded container of the present embodiment may have a plurality of layers B, and the configurations of the plurality of layers B may be the same as or different from each other. The thickness of the layer B can be appropriately determined according to the use and is not particularly limited. However, from the viewpoint of ensuring various physical properties required for the medical multilayer molded container, 50 to 10,000 μm is preferable, and 100 is more preferable. It is -7000 micrometers, More preferably, it is 300-5000 micrometers.

<Polyester>
Specific examples of the polyester used in the layer B of this embodiment are selected from polyhydric carboxylic acids containing dicarboxylic acids and one or more selected from these ester-forming derivatives and polyhydric alcohols containing glycols. The thing which consists of 1 type, or 2 or more types, or what consists of hydroxycarboxylic acid and these ester-forming derivatives, or what consists of cyclic ester etc. are mentioned.

  Specific examples of the dicarboxylic acid include oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, decanedicarboxylic acid, dodecanedicarboxylic acid, tetradecanedicarboxylic acid, hexadecanedicarboxylic acid 3-cyclobutanedicarboxylic acid, 1,3-cyclopentanedicarboxylic acid, 1,2-cyclohexanedicarboxylic acid, 1,3-cyclohexanedicarboxylic acid, 1,4-cyclohexanedicarboxylic acid, 2,5-norbornanedicarboxylic acid, dimer acid Saturated aliphatic dicarboxylic acids exemplified in the above, or ester-forming derivatives thereof, unsaturated aliphatic dicarboxylic acids exemplified in fumaric acid, maleic acid, itaconic acid, etc., or ester-forming derivatives thereof, orthophthalic acid, isophthalic acid ,Terephthalic acid 1,3-naphthalenedicarboxylic acid, 1,4-naphthalenedicarboxylic acid, 1,5-naphthalenedicarboxylic acid, 2,6-naphthalenedicarboxylic acid, naphthalenedicarboxylic acid such as 2,7-naphthalenedicarboxylic acid, 4,4′- Examples include biphenyl dicarboxylic acid, 4,4′-biphenylsulfone dicarboxylic acid, 4,4′-biphenyl ether dicarboxylic acid, 1,2-bis (phenoxy) ethane-p, p′-dicarboxylic acid, anthracene dicarboxylic acid, and the like. Aromatic dicarboxylic acids or their ester-forming derivatives, 5-sodium sulfoisophthalic acid, 2-sodium sulfoterephthalic acid, 5-lithium sulfoisophthalic acid, 2-lithium sulfoterephthalic acid, 5-potassium sulfoisophthalic acid, 2-potassium Exemplified by sulfoterephthalic acid Genus sulfonate group-containing aromatic dicarboxylic acid or lower alkyl ester derivatives thereof, and the like.

  Among the above dicarboxylic acids, terephthalic acid, isophthalic acid, and naphthalenedicarboxylic acids are particularly preferable from the viewpoint of physical properties of the resulting polyester. In addition, you may copolymerize another dicarboxylic acid as needed.

  Specific examples of polycarboxylic acids other than these dicarboxylic acids include ethanetricarboxylic acid, propanetricarboxylic acid, butanetetracarboxylic acid, pyromellitic acid, trimellitic acid, trimesic acid, 3,4,3 ′, 4′-biphenyl. Examples thereof include tetracarboxylic acid and ester-forming derivatives thereof.

  Specific examples of glycols include ethylene glycol, 1,2-propylene glycol, 1,3-propylene glycol, diethylene glycol, triethylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, and 2,3-butylene glycol. 1,4-butylene glycol, 1,5-pentanediol, neopentyl glycol, 1,6-hexanediol, 1,2-cyclohexanediol, 1,3-cyclohexanediol, 1,4-cyclohexanediol, 1,2 -Cyclohexanedimethanol, 1,3-cyclohexanedimethanol, 1,4-cyclohexanedimethanol, 1,4-cyclohexanediethanol, 1,10-decamethylene glycol, 1,12-dodecanediol, polyethylene glycol Aliphatic glycols exemplified by polytrimethylene glycol and polytetramethylene glycol, hydroquinone, 4,4′-dihydroxybisphenol, 1,4-bis (β-hydroxyethoxy) benzene, 1,4-bis ( β-hydroxyethoxyphenyl) sulfone, bis (p-hydroxyphenyl) ether, bis (p-hydroxyphenyl) sulfone, bis (p-hydroxyphenyl) methane, 1,2-bis (p-hydroxyphenyl) ethane, bisphenol A , Bisphenol C, 2,5-naphthalenediol, and aromatic glycols exemplified by glycols obtained by adding ethylene oxide to these glycols.

  Among the above glycols, it is particularly preferable to use ethylene glycol, 1,3-propylene glycol, 1,4-butylene glycol, and 1,4-cyclohexanedimethanol as the main component.

  Specific examples of polyhydric alcohols other than these glycols include trimethylol methane, trimethylol ethane, trimethylol propane, pentaerythritol, glycerol, hexanetriol, and the like.

  Specific examples of the hydroxycarboxylic acid include lactic acid, citric acid, malic acid, tartaric acid, hydroxyacetic acid, 3-hydroxybutyric acid, p-hydroxybenzoic acid, p- (2-hydroxyethoxy) benzoic acid, and 4-hydroxycyclohexanecarboxylic acid. Or ester-forming derivatives thereof.

  Specific examples of the cyclic ester include ε-caprolactone, β-propiolactone, β-methyl-β-propiolactone, δ-valerolactone, glycolide, lactide and the like.

  Specific examples of ester-forming derivatives of polyvalent carboxylic acids and hydroxycarboxylic acids include these alkyl esters, acid chlorides, acid anhydrides and the like.

  Among those described above, a polyester in which the main acid component is terephthalic acid or an ester-forming derivative thereof or naphthalenedicarboxylic acid or an ester-forming derivative thereof, and the main glycol component is alkylene glycol is preferable.

  In addition, the polyester whose main acid component is terephthalic acid or an ester-forming derivative thereof is preferably a polyester containing 70 mol% or more of terephthalic acid or an ester-forming derivative thereof in total with respect to the total acid component, More preferred is a polyester containing 80 mol% or more, and even more preferred is a polyester containing 90 mol% or more. Similarly, the polyester in which the main acid component is naphthalenedicarboxylic acid or an ester-forming derivative thereof is preferably a polyester containing naphthalenedicarboxylic acid or an ester-forming derivative in total of 70 mol% or more, more preferably It is a polyester containing 80 mol% or more, more preferably a polyester containing 90 mol% or more.

  Among the above-mentioned naphthalenedicarboxylic acids or ester-forming derivatives thereof, 1,3-naphthalenedicarboxylic acid, 1,4-naphthalenedicarboxylic acid, 1,5-naphthalenedicarboxylic acid, 2,6-naphthalenedicarboxylic acid exemplified in dicarboxylic acids 2,7-naphthalenedicarboxylic acid or their ester-forming derivatives are preferred.

  Other preferred examples of the polyester used for layer B of the oxygen-absorbing multilayer body of the present embodiment include polyglycolic acid obtained by polycondensation of glycolic acid or methyl glycolate or ring-opening polycondensation of glycolide. It is done. The polyglycolic acid may be one in which other components such as lactide are copolymerized.

  In particular, the polyester used in the layer B of the present embodiment is a polyester in which the main acid component is terephthalic acid or an ester-forming derivative thereof, or naphthalenedicarboxylic acid or an ester-forming derivative thereof, and the main glycol component is alkylene glycol. Is preferred. Moreover, it is preferable that 70 mol% or more of alkylene glycol is included at points, such as a physical characteristic, and it is more preferable that 90 mol% or more is included. Among the dicarboxylic acids described above, terephthalic acid, isophthalic acid, 1,3-naphthalenedicarboxylic acid, 1,4-naphthalenedicarboxylic acid, 1,5-naphthalenedicarboxylic acid, 2,6-naphthalenedicarboxylic acid, The use of 2,7-naphthalenedicarboxylic acid is preferred in terms of the physical properties of the resulting polyester, and preferably contains 70 mol% or more. Among these dicarboxylic acids, terephthalic acid and / or 2,6-naphthalenedicarboxylic acid are particularly preferable. Further, it is preferable that 70 mol% or more of terephthalic acid and / or 2,6-naphthalenedicarboxylic acid is included in terms of physical properties, and more preferably 90 mol% or more. You may copolymerize other dicarboxylic acid as needed. And at least selected from the group consisting of isophthalic acid, diethylene glycol, neopentyl glycol, 1,4-cyclohexanedimethanol, 1,2-propanediol, 1,3-propanediol and 2-methyl-1,3-propanediol. The use of one or more copolymerization components is preferable for achieving both transparency and moldability, and in particular, at least one selected from the group consisting of isophthalic acid, diethylene glycol, neopentyl glycol, and 1,4-cyclohexanedimethanol. The above is more preferable.

  The oxygen-absorbing medical multilayer molded container of the present embodiment has an optional layer in addition to the above-described oxygen-absorbing layer (layer A) and polyester-containing resin layer (layer B) depending on the desired performance and the like. May be included. Examples of such an arbitrary layer include an adhesive layer.

  For example, from the viewpoint of further increasing the interlayer adhesive strength between two adjacent layers, it is preferable to provide an adhesive layer (layer AD) between the two layers. The adhesive layer preferably contains a thermoplastic resin having adhesiveness. As the thermoplastic resin having adhesiveness, for example, an acid modification obtained by modifying a polyolefin resin such as polyethylene or polypropylene with an unsaturated carboxylic acid such as acrylic acid, methacrylic acid, maleic acid, maleic anhydride, fumaric acid or itaconic acid Polyolefin resin; polyester-based thermoplastic elastomer mainly composed of a polyester-based block copolymer. The thickness of the adhesive layer is not particularly limited, but is preferably 2 to 100 μm, more preferably 5 to 90 μm, and still more preferably from the viewpoint of ensuring molding processability while exhibiting practical adhesive strength. Is 10-80 μm.

  The manufacturing method of the oxygen-absorbing medical multilayer molded container of the present embodiment can be applied with known methods according to the properties of various materials, the target shape, etc., and is not particularly limited. For example, a multilayer molded container can be manufactured by applying various injection molding methods.

  The thickness of the oxygen-absorbing medical multilayer molded container of the present embodiment is not particularly limited, but is preferably 3 to 5000 μm from the viewpoint of enhancing oxygen absorption performance and ensuring various physical properties required for the medical multilayer molded container. More preferably, it is 5-4500 micrometers, More preferably, it is 10-4000 micrometers.

  In addition, as a method other than the injection molding method, for example, a multilayer molded body can be obtained by a compression molding method, and the obtained multilayer molded body is subjected to the secondary processing described above to be molded into a desired container shape. You can also For example, a multilayer molded article can be obtained by providing an oxygen-absorbing resin composition in a polyester melt, supplying the molten mass to a male mold, compressing with a female mold, and cooling and solidifying the compression molded article. . Further, as the secondary processing, for example, extrusion molding, compression molding (sheet molding, blow molding) or the like can be applied.

  The usage mode of the oxygen-absorbing medical multilayer molded container of the present embodiment is not particularly limited, and can be used in various applications and forms. Preferred examples of usage include, but are not particularly limited to, vials, ampoules, prefilled syringes, vacuum blood collection tubes, and the like. Hereinafter, preferred usage modes will be described in detail.

[Vial]
The oxygen-absorbing medical multilayer molded container of this embodiment can be used as a vial. In general, a vial is composed of a bottle, a rubber stopper, and a cap. After filling the bottle with a chemical solution, the vial is sealed with a rubber stopper, and the cap is tightened from above to seal the inside of the bottle. The oxygen-absorbing medical multilayer molded container of this embodiment can be used for the bottle portion of this vial.

  As a method for molding the oxygen-absorbing medical multilayer molded container of the present embodiment into the bottle portion of the vial, for example, injection blow molding, extrusion blow molding and the like are suitable. As a specific example, an injection blow molding method is shown below. For example, using a molding machine equipped with two or more injection machines and an injection mold, the material constituting the layer A and the material constituting the layer B are passed through the mold hot runners from the respective injection cylinders, and the injection mold. By injecting into the cavity of the mold, a multilayer injection molded body having a three-layer structure B / A / B having a shape corresponding to the cavity shape of the injection mold can be manufactured. First, the material constituting the layer B is injected from the injection cylinder, then the material constituting the layer A is injected from another injection cylinder simultaneously with the resin constituting the layer B, and then the resin constituting the layer B By injecting a necessary amount of the solution to fill the cavity, a multilayer injection molded body having a three-layer structure B / A / B can be manufactured. Furthermore, by first injecting the material constituting the layer B, then injecting the material constituting the layer A alone, and finally injecting the necessary amount of the material constituting the layer B to fill the mold cavity, A multilayer injection molded article having a five-layer structure B / A / B / A / B can be produced. Still further, first, the material constituting the layer B1 is injected from the injection cylinder, then the material constituting the layer B2 is injected from another injection cylinder simultaneously with the resin constituting the layer B1, and then the layer A is constituted. By injecting the resin simultaneously with the resins constituting the layers B1 and B2, and then injecting a necessary amount of the resin constituting the layer B1 to fill the cavity, the five-layer structure B1 / B2 / A / B2 / B1 A multilayer injection molded article can be produced. In this injection blow molding, the multilayer injection molded body obtained by the above method is fitted in a final shape mold (blow mold) while being heated to some extent, and air is blown and inflated into the mold. It can be formed into a bottle shape by closely contacting and solidifying by cooling.

〔ampoule〕
Moreover, the oxygen-absorbing medical multilayer molded container of the present embodiment can be used as an ampoule. In general, an ampoule is composed of a small container having a narrow neck, and the container is hermetically sealed by filling the container with a chemical solution and then sealing the tip of the neck. The oxygen-absorbing medical multilayer molded container of this embodiment can be used for this ampoule (small container). As a method of forming the oxygen-absorbing medical multilayer molded container of this embodiment into an ampoule, for example, injection blow molding, extrusion blow molding and the like are suitable.

[Prefilled syringe]
Furthermore, the oxygen-absorbing medical multilayer molded container of the present embodiment can be used as a prefilled syringe. In general, a prefilled syringe is composed of at least a barrel for filling a liquid medicine, a joint for joining an injection needle to one end of the barrel, and a plunger for pushing out the liquid medicine at the time of use. Is a syringe that is configured so that the tip of the barrel is unsealed and a syringe needle is attached during use, and is widely used for its ease of use. The oxygen-absorbing medical multilayer molded container of this embodiment can be used for this barrel.

  As a method of molding the oxygen-absorbing medical multilayer molded container of the present embodiment into the barrel of a prefilled syringe, for example, an injection molding method is suitable. Specifically, first, a certain amount of resin constituting the layer B is injected into the cavity of the injection mold, then a certain amount of resin constituting the layer A is injected, and a certain amount of resin constituting the layer B is again injected. By injecting, a barrel can be manufactured as a multilayer injection molded article. It should be noted that the barrel and the joint may be molded as an integral part, or may be joined separately. Moreover, after filling the chemical solution, it is necessary to seal the tip of the joint, but the method is not particularly limited, and a known method can be adopted. For example, the resin at the tip of the joint may be heated to a molten state and sandwiched with pliers or the like to be fused.

  The thickness of the container of the barrel of the prefilled syringe can be appropriately set according to the purpose of use and size, and is not particularly limited. In general, from the viewpoint of long-term storage stability of the chemical solution, moldability, and operability of the syringe, about 0.5 to 20 mm is preferable, and about 0.5 to 5 mm is more preferable. Moreover, even if thickness is uniform, what changed thickness may be sufficient. Further, another gas barrier film or a light shielding film may be further formed on the barrel surface for the purpose of long-term storage stability. These arbitrary films and the formation method thereof are described in, for example, Japanese Patent Application Laid-Open No. 2004-323058.

[Vacuum blood collection tube]
Moreover, the oxygen-absorbing medical multilayer molded container of the present embodiment can be used as a vacuum blood collection tube. In general, the vacuum blood collection tube is composed of a tubular body and a stopper. The oxygen-absorbing medical multilayer molded container of this embodiment can be used for this tubular body.

  As a method for forming the oxygen-absorbing medical multilayer molded container of this embodiment into a tubular body of a vacuum blood collection tube, for example, an injection molding method is suitable. Specifically, first, a certain amount of resin constituting the layer B is injected into the cavity of the injection mold, then a certain amount of resin constituting the layer A is injected, and a certain amount of resin constituting the layer B is again injected. By injecting, a tubular body can be produced as a multilayer injection molded body.

[Contained items]
The material to be stored (filled material) filled in the oxygen-absorbing medical multilayer molded container of the present embodiment is not particularly limited. For example, vitamins such as vitamin A, vitamin B2, vitamin B12, vitamin C, vitamin D, vitamin E, and vitamin K, alkaloids such as atropine, hormones such as adrenaline and insulin, sugars such as glucose and maltose, ceftriaxone Any natural products and compounds such as antibiotics such as cephalosporin and cyclosporine, and benzodiazepines such as oxazolam, flunitrazepam, clothiazepam and clobazam can be filled. The oxygen-absorbing medical multilayer molded container of the present embodiment, when filled with these natural products and compounds, has a small amount of adsorption of these natural products and compounds, and can suppress alteration due to oxidation, Moreover, transpiration of the solvent (for example, moisture) can be suppressed.

  In addition, before and after the filling of these objects to be stored, the medical multilayer container and the objects to be stored can be sterilized in a form suitable for the objects to be stored. As sterilization methods, for example, hot water treatment at 100 ° C. or lower, pressurized hot water treatment at 100 ° C. or higher, high temperature heat treatment at 121 ° C. or higher, etc., electromagnetic wave sterilization of ultraviolet rays, microwaves, gamma rays, etc., ethylene Examples include gas treatment of oxide and the like, and chemical sterilization such as hydrogen peroxide and hypochlorous acid.

    Hereinafter, the oxygen-absorbing medical multilayer molded container of the present invention will be described in more detail using Examples and Comparative Examples, but the present invention is not limited thereto. In the following examples, vials have been demonstrated as examples. However, as shown in the present specification, the required characteristics for ampoules, prefilled syringes, and vacuum blood collection tubes are the same as those for vials. Is not limited in any way by the following examples. Unless otherwise specified, NMR measurements were performed at room temperature.

[Monomer synthesis example]
(Synthesis Example 1)
An autoclave having an internal volume of 18 L was charged with 2.20 kg of dimethyl naphthalene-2,6-dicarboxylate, 11.0 kg of 2-propanol, and 350 g (50 wt% water-containing product) of 5% palladium supported on activated carbon. Next, after the air in the autoclave was replaced with nitrogen, and further nitrogen was replaced with hydrogen, hydrogen was supplied until the pressure in the autoclave reached 0.8 MPa. Next, the agitator was started, the rotation speed was adjusted to 500 rpm, the internal temperature was raised to 100 ° C. over 30 minutes, and hydrogen was further supplied to a pressure of 1 MPa. Thereafter, the supply of hydrogen was continued to maintain 1 MPa in accordance with the pressure drop due to the progress of the reaction. Since the pressure drop disappeared after 7 hours, the autoclave was cooled, unreacted residual hydrogen was released, and then the reaction solution was taken out from the autoclave. The reaction solution was filtered to remove the catalyst, and then 2-propanol was evaporated from the separated filtrate with an evaporator. To the obtained crude product, 4.40 kg of 2-propanol was added and purified by recrystallization to obtain dimethyl tetralin-2,6-dicarboxylate in a yield of 80%. The NMR analysis results are as follows. 1H-NMR (400 MHz CDCl ₃ ) δ7.76-7.96 (2H m), 7.15 (1H d), 3.89 (3H s), 3.70 (3H s), 2.70-3.09 (5H m), 1.80-1.95 (1H m ).

Next, 1.00 kg of dimethyl tetralin-2,6-dicarboxylate obtained above, 8.0 kg of a 16 wt% aqueous ethanol solution and 360 g of sodium hydroxide were added to a 10 L flask, and the mixture was stirred at 80 ° C. for 4 hours for hydrolysis. . Thereafter, 36% hydrochloric acid was added until the pH reached 7, and the precipitated tetralin-2,6-dicarboxylic acid was separated by filtration and then vacuum-dried to obtain 90% yield. The NMR analysis results are as follows. 1H-NMR (400 MHz ((D ₃ C) ₂ S═O) δ12.41-12.75 (2H br), 7.65 (2H m), 7.23 (1H d), 3.70 (3H s), 2.60-3.45 (5H m ), 2.05-2.13 (1H m), 1.70-1.79 (1H m).

[Polymer production example]
(Production Example 1)
In a 200 mL autoclave equipped with a thermometer, a pressure gauge, a nitrogen inlet, and a pressure outlet, 17.18 g (78.0 mmol) of tetralin-2,6-dicarboxylic acid obtained in Synthesis Example 1 and 15.63 g of dodecamethylenediamine ( 78.0 mmol) and 19 g of distilled water were charged, and the inside of the container was purged with nitrogen. The temperature was raised to 220 ° C. over 2 hours and held at a pressure of 2 MPaG for 2 hours. Thereafter, the temperature is raised to 320 ° C. over 1 hour, the pressure is lowered to normal pressure during the temperature rise, and the tetralin ring-containing polyamide compound (1 is cooled by holding at 320 ° C. and normal pressure for 30 minutes. ) As a result of measuring the glass transition temperature and melting | fusing point of the obtained polyamide compound (1) by DSC, the glass transition temperature was 111 degreeC and melting | fusing point was 262 degreeC. The relative viscosity was 3.74. The charge composition is shown in Table 1.

(Production Example 2)
In the same autoclave as in Production Example 1, 11.64 g (52.9 mmol) of tetralin-2,6-dicarboxylic acid obtained in Synthesis Example 1, 2.48 g (13.2 mmol) of azelaic acid, 13.24 g of dodecamethylenediamine ( 66.1 mmol) and 12 g of distilled water were charged, and a tetralin ring-containing polyamide compound (2) was synthesized in the same manner as in Production Example 1. Polyamide compound (2) had a glass transition temperature of 94 ° C., a melting point of 246 ° C., and a relative viscosity of 3.5. The charge composition is shown in Table 1.

(Production Example 3)
In an autoclave similar to Production Example 1, 15.11 g (68.6 mmol) of tetralin-2,6-dicarboxylic acid obtained in Synthesis Example 1, 13.88 g (68.6 mmol) of sebacic acid, 15.95 g of hexamethylenediamine ( 137.2 mmol) and 12 g of distilled water were charged, and a tetralin ring-containing polyamide compound (3) was synthesized in the same manner as in Production Example 1. Polyamide compound (3) had a glass transition temperature of 87 ° C., a melting point of 250 ° C., and a relative viscosity of 2.6. The charge composition is shown in Table 1.

(Production Example 4)
In the same autoclave as in Production Example 1, 11.22 g (51.0 mmol) of tetralin-2,6-dicarboxylic acid obtained in Synthesis Example 1, 5.93 g (50.9 mmol) of hexamethylenediamine, 11.54 g of ε-caprolactam (102.0 mmol) and 12 g of distilled water were charged, and a tetralin ring-containing polyamide compound (4) was synthesized in the same manner as in Production Example 1. Polyamide compound (4) had a glass transition temperature of 96 ° C., a melting point of 219 ° C., and a relative viscosity of 2.4. The charge composition is shown in Table 1.

Example 1
A biaxial extrusion having two screws with a diameter of 37 mm, obtained by dry blending cobalt stearate (II) with a cobalt content of 0.1 parts by mass with respect to 100 parts by mass of the polyamide compound (1) The oxygen-absorbing resin composition (1) is supplied to the machine at a rate of 15 kg / h, melt kneaded at a cylinder temperature of 290 ° C., extruding a strand from the extruder head, cooling, and pelletizing. Obtained. Next, as shown below, a vial which is a multilayer injection-molded container was produced using this oxygen-absorbing resin composition (1). Then, the performance evaluation of the obtained vial was performed as shown below. The evaluation results are shown in Table 2.

[Manufacture of vials]
Under the following conditions, the polyester constituting the resin layer (layer B) is injected from the injection cylinder, and then the oxygen-absorbing resin composition (1) constituting the oxygen absorbing layer (layer A) is separated from another injection cylinder. B / A / B three-layer injection molded body is obtained by injecting together with the polyester composing B and then injecting the required amount of polyester composing layer B to fill the cavity in the injection mold. It was. Thereafter, the obtained injection-molded product was cooled to a predetermined temperature, transferred to a blow mold, and blow-molded to produce a vial (bottle part). Here, the total mass of the vial was 24 g, and the mass of the layer A was 30% by mass of the total mass of the vial. Moreover, as polyester which comprises the layer B, the polyethylene terephthalate resin (Nippon Unipet Corporation make, brand name: RT-553C) was used.

(Vial shape)
The total length was 89 mm, the outer diameter was 40 mmφ, and the wall thickness was 1.8 mm. For the manufacture of the vial, an injection blow integrated molding machine (manufactured by UNILOY, model: IBS 85, 4 pieces) was used.
(Vial molding conditions)
Injection cylinder temperature for layer A: 280 ° C
Injection cylinder temperature for layer B: 280 ° C
Resin channel temperature in injection mold: 280 ° C
Blow temperature: 150 ° C
Blow mold cooling water temperature: 15 ° C

[Performance evaluation of vials]
The obtained vial was measured for oxygen permeability, appearance after molding, drop test, and dissolution test according to the following methods and standards.

(1) Vials oxygen permeability (OTR)
The oxygen permeability on the 30th day from the start of measurement was measured in an atmosphere of 23 ° C., 50% relative humidity outside the molded body, and 100% relative humidity inside the molded body. For the measurement, an oxygen permeability measuring device (manufactured by MOCON, trade name: OX-TRAN 2-21 ML) was used. It shows that oxygen barrier property is so favorable that a measured value is low. The lower limit of detection of the measurement is an oxygen transmission rate of 5 × 10 ⁻⁵ mL / (0.21 atm · day · package).

(2) Vapor water vapor transmission rate (WVTR)
The water vapor transmission rate on the 10th day from the start of measurement was measured in an atmosphere of 40 ° C. and 100% relative humidity outside the molded body. The measurement used the water-vapor-permeation rate measuring apparatus (The product name: PERMATRAN-W 3 / 33G by MOCON). It shows that water vapor | steam barrier property is so favorable that a measured value is low. The lower limit of detection of the measurement is a water vapor transmission rate of 5 × 10 ⁻⁴ g / (day · package).

(3) Appearance after molding The presence or absence of whitening of the vial after molding was visually observed.

(4) Drop test After the vial was stored at 40 ° C. and 90% RH for one month, it was filled with 50 mL of pure water, and then sealed with a rubber stopper and an aluminum cap. The sealed container thus obtained was dropped from a height of 2 m, and the appearance of the container at that time was examined.

(5) Dissolution test After the vial was stored at 40 ° C. and 90% RH for one month, it was filled with 50 mL of pure water, and then sealed with a rubber stopper and an aluminum cap. The sealed container thus obtained was stored at 40 ° C. and 60% RH for 4 months, and then the total carbon content (hereinafter referred to as TOC) in pure water was measured.
(TOC measurement)
Device: TOC-V _CPH manufactured by Shimadzu Corporation
Combustion furnace temperature: 720 ° C
Gas and flow rate: High-purity air, TOC meter section 150 mL / min
Injection volume: 150 μL
Detection limit: 1 μg / mL

(Examples 2 to 4)
An oxygen-absorbing resin composition and a vial were produced in the same manner as in Example 1 except that the polyamide compounds shown in Table 2 were used instead of the polyamide compound (1). The performance evaluation of the obtained vial was performed in the same manner as in Example 1. The evaluation results are shown in Table 2.

(Comparative Example 1)
Except for using 100 parts by mass of a cycloolefin copolymer manufactured by Ticona GmbH (TOPAS 6013 manufactured by Ticona GmbH) instead of the oxygen-absorbing resin composition (1), the same procedure as in Example 1 was performed. Single layer vials were produced. The performance evaluation of the obtained vial was performed in the same manner as in Example 1. The evaluation results are shown in Table 2.

(Comparative Example 2)
A vial was manufactured in the same manner as in Example 1 except that polycarbonate (Lexan 144R manufactured by Sabic) was used as the thermoplastic resin constituting the layer B instead of polyethylene terephthalate resin. The performance evaluation of the obtained vial was performed in the same manner as in Example 1. The evaluation results are shown in Table 2.

(Comparative Example 3)
A mixture obtained by dry blending cobalt stearate (II) so that the amount of cobalt becomes 0.04 parts by mass with respect to 100 parts by mass of nylon MXD6 (S7007 manufactured by Mitsubishi Gas Chemical Co., Ltd.) Oxygen-absorbing resin is supplied to a twin screw extruder having two at a rate of 15 kg / h, melt kneaded at a cylinder temperature of 280 ° C., extruding a strand from the extruder head, cooling, and pelletizing. A composition (M) was obtained. A vial was produced in the same manner as in Example 1 except that this oxygen-absorbing resin composition (M) was used instead of the oxygen-absorbing resin composition (1). The performance evaluation of the obtained vial was performed in the same manner as in Example 1. The evaluation results are shown in Table 2.

  As is clear from Table 2, the vials of Examples 1 to 4 have good oxygen barrier properties and water vapor barrier properties, maintain good strength even after long-term storage, and the amount of elution from the container to the contents also It was confirmed to be low. Furthermore, it was confirmed that the vials of Examples 1 to 4 have excellent visibility inside the container and are excellent in transparency.

Claims (8)

At least three layers of a first resin layer containing at least polyester, an oxygen absorbing layer composed of an oxygen absorbing resin composition containing a polyamide compound and a transition metal catalyst, and a second resin layer containing at least polyester An oxygen-absorbing medical multilayer molded container having in order,
The polyamide compound is a structural unit represented by the following general formulas (1) to (2);

(In the formula, each R independently represents a monovalent substituent, which is a halogen atom, alkyl group, alkenyl group, alkynyl group, aryl group, heterocyclic group, cyano group, hydroxy group, Selected from the group consisting of a group, carboxyl group, ester group, amide group, nitro group, alkoxy group, aryloxy group, acyl group, amino group, mercapto group, alkylthio group, arylthio group, heterocyclic thio group and imide group And each of them may further have a substituent, wherein each m independently represents an integer of 0 to 3, and in each formula, n is each independently Represents an integer of 0 to 7, and at least one hydrogen atom is bonded to the benzylic position of the tetralin ring, wherein each X is independently an aromatic hydrocarbon group, saturated or unsaturated. Sat It shows the alicyclic hydrocarbon group, a divalent group containing at least one group selected from the group consisting of aliphatic hydrocarbon group and the heterocyclic group of linear or branched, saturated or unsaturated.)
Containing at least one tetralin ring selected from the group consisting of , wherein the transition metal catalyst comprises at least one transition metal selected from the group consisting of manganese, iron, cobalt, nickel and copper An oxygen-absorbing medical multilayer molded container. The oxygen-absorbing medical multilayer molded container according to claim 1, wherein the transition metal catalyst is contained in an amount of 0.001 to 10 parts by mass as a transition metal amount with respect to 100 parts by mass of the polyamide compound. The structural unit represented by the general formula (1) is represented by the following formulas (3) to (6);

At least one selected from the group consisting of:
The oxygen-absorbing medical multilayer molded container according to claim 1 or 2 . 70% by mole or more of the polyester in the dicarboxylic acid unit is terephthalic acid, isophthalic acid, 1,3-naphthalenedicarboxylic acid, 1,4-naphthalenedicarboxylic acid, 1,5-naphthalenedicarboxylic acid, 2,6-naphthalenedicarboxylic acid. The oxygen-absorbing medical multilayer molded container according to any one of claims 1 to 3 , which is derived from at least one dicarboxylic acid selected from the group consisting of an acid and 2,7-naphthalenedicarboxylic acid. The oxygen-absorbing medical multilayer molded container according to any one of claims 1 to 3 , wherein 70% by mole or more of the polyester in the dicarboxylic acid unit is derived from terephthalic acid. The oxygen-absorbing medical multilayer molded container according to any one of claims 1 to 3 , wherein 90% by mole or more of the polyester in the dicarboxylic acid unit is derived from terephthalic acid. The oxygen-absorbing medical multilayer molded container according to any one of claims 1 to 3 , wherein 70% by mole or more of the polyester in the dicarboxylic acid unit is derived from 2,6-naphthalenedicarboxylic acid. The oxygen-absorbing medical multilayer molded container according to any one of claims 1 to 3 , wherein 90% by mole or more of the polyester in the dicarboxylic acid unit is a 2,6-naphthalenedicarboxylic acid skeleton.